Non-Coding RNA (Aug 2022)

Liquid Biopsy and Circulating Biomarkers for the Diagnosis of Precancerous and Cancerous Oral Lesions

  • Giuseppe Gattuso,
  • Salvatore Crimi,
  • Alessandro Lavoro,
  • Roberta Rizzo,
  • Giorgia Musumarra,
  • Simona Gallo,
  • Flavia Facciponte,
  • Sabrina Paratore,
  • Angela Russo,
  • Roberto Bordonaro,
  • Gaetano Isola,
  • Alberto Bianchi,
  • Massimo Libra,
  • Luca Falzone

DOI
https://doi.org/10.3390/ncrna8040060
Journal volume & issue
Vol. 8, no. 4
p. 60

Abstract

Read online

Oral cancer is one of the most common malignancies worldwide, accounting for 2% of all cases annually and 1.8% of all cancer deaths. To date, tissue biopsy and histopathological analyses are the gold standard methods for the diagnosis of oral cancers. However, oral cancer is generally diagnosed at advanced stages with a consequent poor 5-year survival (~50%) due to limited screening programs and inefficient physical examination strategies. To address these limitations, liquid biopsy is recently emerging as a novel minimally invasive tool for the early identification of tumors as well as for the evaluation of tumor heterogeneity and prognosis of patients. Several studies have demonstrated that liquid biopsy in oral cancer could be useful for the detection of circulating biomarkers including circulating tumor DNA (ctDNA), microRNAs (miRNAs), proteins, and exosomes, thus improving diagnostic strategies and paving the way to personalized medicine. However, the application of liquid biopsy in oral cancer is still limited and further studies are needed to better clarify its clinical impact. The present manuscript aims to provide an updated overview of the potential use of liquid biopsy as an additional tool for the management of oral lesions by describing the available methodologies and the most promising biomarkers.

Keywords